Earnings call transcript: Devyser Q3 2026 profit improves as stock rises 5.7%

Devyser’s Q3 revenue rose 5.8% year over year to SEK 59.7 million, while EBIT increased to SEK 7.1 million from SEK 1.3 million and operating cash flow reached SEK 22 million versus negative SEK 0.5 million a year earlier. Gross margin recovered to 83%, and shares gained 5.69% to $65 in pre-market trading. The largest distributor placed no orders in the quarter; management expects sales to remain weak through the rest of 2026 and normalize toward 2025 levels during 2027. Devyser expanded its transplant-monitoring product to heart and lung patients, while its 30% long-term growth target depends on successful MolDx and later FDA approvals.

Analysis

The quarter improves the case that Devyser can defend profitability through a channel shock, but it does not yet validate a durable growth re-acceleration. The key distinction is between operating leverage and demand: cost actions and pricing lifted earnings while the largest distributor placed no orders. If that channel remains suppressed into 2027, strong margins may not prevent revenue stagnation.

Near term, the stock’s premarket gain risks pricing in a cleaner recovery than management can currently substantiate. Its visibility into the distributor’s inventory is explicitly incomplete, making the 2027 normalization assumption the principal earnings-estimate risk. The cash-flow improvement is encouraging but should not be annualized without a working-capital bridge; inventory and receivables movements can make quarterly cash conversion lumpy.

Over 1–3 months, watch for evidence of new orders through Thermo Fisher, reagent-rental installations translating into consumable sales, and the expected MolDx decision. Heart/lung expansion is strategically useful but likely a multi-quarter adoption story, not a near-term offset to distributor weakness. Over 6–18 months, reimbursement and FDA progress could broaden the addressable market; failure would leave the 30% growth ambition unsupported. Natera’s transplant-monitoring offering is a competitive reference point: broader organ coverage matters only if clinical adoption and reimbursement follow.

Contrarian read: the margin recovery may be more durable than the sales recovery, but the market may be underweight the possibility that distributor normalization is delayed. Also verify the tradable instrument and quote currency before acting: the article quotes a dollar price, while the supplied identity maps Devyser to XSTO.

Key Decisions for Investors

• Do not chase the immediate post-results move. Keep DVYSR on a conditional long watchlist; consider entry only after evidence of distributor reorders or a confirmed MolDx outcome, with position sizing reflecting binary reimbursement and channel risks.
• For the next 1–3 months, monitor quarterly revenue by channel, distributor order trends, and cash-flow composition. A further weak sales print alongside sustained rolling gross margin above 80% would support the efficiency thesis; margin slippage plus continued channel weakness would falsify it.
• Treat heart/lung expansion and Illumina reagent rentals as upside options, not base-case near-term earnings drivers. Verify installations, repeat kit orders, and customer validation before raising estimates.
• Before trading, reconcile the article’s dollar-denominated quote with the XSTO listing and confirm the correct security, currency, liquidity, and available market data.